Skip to main content

Table 2 Patient characteristics

From: A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Patient characteristics

No. of patients (%)

n = 14

Sex

 Male

 Female

4 (28.6)

10 (71.4)

Age

 Median age, years (range)

54,5 (35–72)

ECOG performance status

 O

 1

 2

8 (57.1)

5 (35.7)

1 (7.1)

Primary tumor location

 Breast

 Rectum

 Stomach

 Othersa

5 (35.7)

3 (21.4)

3 (21.4)

3 (21.4)

No. of organs involved (primary excluded)

 1

 2

 3

 ≥4

5 (35.7)

3 (21.4)

2 (14.3)

4 (28.6)

Organs involved (primary tumor excluded)

 Lymph nodes

 Lung

 Liver

 Abdominal Wall

 Bone

 Othersb

7 (50.0)

5 (35.7)

3 (21.4)

3 (21.4)

3 (21.4)

10 (71.4)

Her2 status

 IHC 2+/ISH+

 IHC 3+

3 (21.4)

11 (78.6)

  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, IHC immunohistochemistry, ISH in-situ hybridisation
  2. aOthers: head and neck (2 pts), pancreas (1 pt)
  3. bOthers: adrenal gland, spleen, bladder, lymphangiosis carcinomatosa, pleura, peritoneum, chest wall, brain, skin